|Day Low/High||54.08 / 54.72|
|52 Wk Low/High||46.01 / 77.12|
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Jim Cramer is bullish on United States Steel and Universal Display, less so with Arconic and Himax Technologies.
Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.
Tom Price will now head the Department of Health and Human Services.
Jim Cramer compares Allergan's growth to other pharma stocks.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Annual Global Health Care Conference on Wednesday, February 15, 2017, in New York.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.
On an earnings call, Merck CEO Kenneth Frazier said the company will continue to seek opportunities with a particular focus on augmenting its early- to mid-stage pipeline.
As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their long-term needs, according to a new Bristol-Myers...
Merck posts fourth-quarter earnings largely in line with estimates but issues a cautious outlook for the year.
Analysts have forecast fourth-quarter sales of $470 million for Merck's cancer drug Keytruda.
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Patent Office (EPO) upheld a decision with regard to European Patent No.
Two industries should largely be avoided under this administration: pharma and retail.
Investors will be listening for details around competition facing key products and plans for capital deployment.
Doug Kass shares his thoughts on Starbucks, and discusses what, if anything, Dow 20,000 means.
Selling a call on Bristol-Myers Squibb would help investors limit their risk as the pharmaceutical company's volatility increased recently.
On an earnings call this morning, Bristol-Myers CEO Giovanni Caforio noted that the company has a broad front-line lung cancer program.
The Dow Jones Industrial Average scores a record close for its second day in a row, benefiting from a small bump that cemented its position above 20,000.
The Dow Jones Industrial Average is on track to squeeze out another record close, its second in a row, in a mixed session.
Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.
Stocks hold mixed on Thursday as markets run out of steam to push a record-breaking rally into day two.
Stock futures turn mixed on Thursday as investors take pause after Wednesday's history-making rally.
Stocks hit record highs this week, indicating that the postelection surge still has momentum. Bargains are hard to find, but this health giant is a smart value play now.
McKesson, Bristol-Myers and Varian were having a busy morning.